Ketanserin plus prostaglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone

Br J Urol. 1996 May;77(5):736-9. doi: 10.1046/j.1464-410x.1996.97722.x.

Abstract

Objective: To evaluate the treatment of patients with erectile dysfunction and who were unresponsive to intracavernosal injections of prostaglandin E-1 (PGE-1) alone with a combination of PGE-1 and ketanserin, a peripheral vasodilator antagonizing 5-hydroxytryptamine receptors and with mild alpha-blocking effects.

Patients and methods: The study comprised 98 men with erectile dysfunction all of whom received an intracavernosal injection of 5-40 micrograms of PGE-1. The 45 patients unresponsive to the maximum dose of 40 micrograms were selected for further treatment using a combined dose of 40 micrograms PGE-1 and 2-7 mg of ketanserin. Their erectile response was assessed both subjectively, by interviewing the patient and their partner, and objectively using the 'Rigiscan' monitor.

Results: The combined therapy was effective in producing an erection sufficient for sexual intercourse in 34 (76%) of the patients. The combined dose was tolerated well and there were no adverse effects.

Conclusions: The results of this preliminary study suggest that the combination of PGE-1 and ketanserin may be a therapeutic alternative to the implantation of a prosthesis in patients unresponsive to PGE-1.

MeSH terms

  • Alprostadil / administration & dosage
  • Alprostadil / therapeutic use*
  • Drug Combinations
  • Humans
  • Impotence, Vasculogenic / drug therapy*
  • Injections
  • Ketanserin / administration & dosage
  • Ketanserin / therapeutic use*
  • Male
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use*

Substances

  • Drug Combinations
  • Vasodilator Agents
  • Ketanserin
  • Alprostadil